Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
267 articles with Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019
The live conference call on Tuesday, November 5, 2019, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 2980632.
9/20/2019Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.
Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors.
Company will participate in the following conferences in September.
Portola Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share.
Portola Pharmaceuticals, Inc.® announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering.
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019, and provided a corporate update.
Expands Patient Access to the First and Only Factor Xa Reversal Agent Approved in Europe for Life-Threatening Bleeds Associated with the Use of Rivaroxaban or Apixaban
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
Add-on Payment Increased from 50 to 65 Percent; Supports Patient Access by Providing Additional Medicare Reimbursement in the Hospital Setting
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com.
Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors
Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis
Here’s a roundup of some of the top clinical trial news from the previous week.
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the European Commission (EC) has granted conditional Marketing Authorization for Ondexxya™ (andexanet alfa)
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authorization application (MAA) for Ondexxya™ (andexanet alfa).
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief commercial officer, effective immediately.
U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process
– Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban – – Full Commercial Launch to Begin January 2019
With the holidays upon us, along with the end of 2018 and the beginning of 2019, the FDA squeezed some target action dates into the last weeks and beginning of the new year. As it turned out, these appear to be a mixed bag of extensions, resubmissions and supplemental applications, some of which ...
Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B.